Evaluation of the Survival Rate and Clinical Outcome of Nanodrug Administration for the Treatment of Lung Cancer: A Systematic Review and Meta-analysis

Abstract

Background and aim: During the last two decades, with the introduction of nanotechnology, a more promising perspective for cancer treatment appeared, and many research was conducted in nanomedicine. Based on the findings of studies, nanoparticles improve bioavailability, overcome biophysical and biochemical barriers, and reduce cytotoxicity. This study aims to evaluate the survival rate and clinical outcome of nanodrug administration for lung cancer treatment.Material and methods: In this study, international databases such as PubMed, Scopus, Science Direct, ISI, Web of Knowledge, and Embase were reviewed to select articles related to the purpose of this study from January 2012 to July 2022. Effect size with 95% confidence interval (CI) with fixed effect modal and inverse-variance done. STATA.V16 software was used for data analysis.Results: In the initial review, the abstracts of 183 studies were reviewed, two authors reviewed the full text of 34 studies, and finally, seven studies were selected. Overall survival rate and Progression-Free survival rate between nab-paclitaxel plus carboplatin compared solvent-based paclitaxel plus cisplatin in lung cancer patients was 88% (HR: 95% CI, 0.51 to 1.25; p=0.00) and 77% (HR: 95% CI, 0.37 to 1.17; p=0.00), respectively.Conclusions: Based on the findings of the present meta-analysis, nab-paclitaxel administration can prolong the progression-free survival rate; improve the objective response rate, and increase the overall survival rate.

Keywords

• lung neoplasms
• nanoparticles
• nanoparticle drug delivery system